AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
February 07, 2025 16:05 ET | Source: AEON Biopharma IRVINE, Calif., Feb.…
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
Topline data from Phase 3 ONWARD trials for Alumis’ ESK-001 in moderate-to-severe…
Comanche Biopharma Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway (ILAP) Steering Group for CBP-4888, an Investigational siRNA Drug Candidate for the Treatment of sFlt1-mediated Preterm Preeclampsia
January 30, 2025 05:00 ET | Source: Comanche Biopharma ILAP aims to…
ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers
January 21, 2025 19:00 ET | Source: ArriVent BioPharma, Inc. Exclusive global…
Matinas BioPharma Receives NYSE Noncompliance Notice
January 10, 2025 17:15 ET | Source: Matinas BioPharma Holdings, Inc. BEDMINSTER,…
Matinas BioPharma Receives NYSE Noncompliance Notice
January 10, 2025 17:15 ET | Source: Matinas BioPharma Holdings, Inc. BEDMINSTER,…
AEON Biopharma, Inc. Announces Launch of Proposed Public Offering
January 03, 2025 20:02 ET | Source: AEON Biopharma IRVINE, Calif., Jan.…
Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media
- Company management will provide an update on positive new developments regarding…
New Report from Clarivate and Healthcare Executive Explores Mainland China’s Biopharma Revolution and Increasing Global Influence
New report analyses Mainland China's transformation into a global biopharma powerhouse, with…
